VALGANCARE contains valganciclovir, an antiviral agent that is converted into ganciclovir inside the body. It works by inhibiting viral DNA synthesis and preventing CMV replication.
Recommended for:
Valganciclovir has been extensively studied in international clinical trials involving transplant recipients and HIV-positive patients. Clinical studies demonstrated effectiveness in reducing viral load, preventing CMV disease, and slowing the progression of CMV retinitis. The medication is widely used in modern antiviral therapy according to international treatment guidelines.
The medication is indicated for the treatment of CMV retinitis in immunocompromised patients and for prevention of CMV infection following organ transplantation. Valganciclovir inhibits viral replication and helps reduce the risk of severe viral complications.
The medication is taken orally with food as prescribed by a physician. Dosage and treatment duration depend on the diagnosis, kidney function, and immune status of the patient. Regular blood count and kidney function monitoring are recommended during therapy.
Contraindications:
Side effects:
